Researchers are excited about Retatrutide , a novel dual agonist showing significant results in initial trials for body reduction . It acts by targeting both hormones : GLP-1 and GIP, which , when https://jakubczxg285195.vidublog.com/39519943/the-new-hope-for-body-management